BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Antibody Drug Conjugates

Mabwell’s B7-H3-Targeting ADC 7MW3711 Enters Phase Ib/II Trial in China for Advanced Solid Tumors

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) ha...

April 03, 2025 | News

Sichuan Kelun-Biotech Gets Green Light for First Radionuclide-Drug Conjugate Clinical Trial

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical trial notice approving the invest...

March 26, 2025 | News

China’s Innovent Doses First Patient in Phase 3 Trial of HER2-Targeted ADC for Ovarian Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

March 25, 2025 | Report

Harbour BioMed and AstraZeneca Announce $4.6B Global Collaboration on Next-Gen Multi-Specific Antibodies

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody...

March 24, 2025 | News

Alphamab Oncology and CSPC’s Anti-HER2 ADC JSKN003 Secures Breakthrough Therapy Designation in China

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic...

March 19, 2025 | News

Pierre Fabre and RedRidge Bio Partner to Develop Biparatopic Antibody Drug Candidates

Pierre Fabre Laboratories and RedRidge Bio announced an exclusive R&D collaboration and license agreement to identify and develop biparatopic...

March 13, 2025 | News

Navigating Biologics Development: Strategies for Regulatory Success, CMC Challenges, and Tech Transfer

Click here to Register Now! As the biologics field rapidly evolves, mastering regulatory pathways, process development, and tech transfer is essential for...

March 12, 2025 | News

WuXi XDC and AbTis Partner to Advance Site-Selective ADC Conjugation

WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organiza...

March 12, 2025 | News

Sichuan Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan Secures NMPA Approval for EGFR-Mutant NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP...

March 11, 2025 | News

Nona Biosciences Unveils AI-Powered Hu-mAtrIx™ Platform to Transform Antibody Discovery

Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), announced to unveil its innovative AI-...

March 10, 2025 | News

CStone Pharmaceuticals Advances CS5001 with Phase Ib Trial Application in Australia for First-Line DLBCL Treatment

Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape ...

March 06, 2025 | News

Frazier Life Sciences Launches Callio Therapeutics with $187M Series A to Advance Multi-Payload ADCs

Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from&nb...

March 05, 2025 | News

WuXi Biologics Introduces EffiX™ a High-Yield E. coli Expression Platform for Recombinant Proteins and Plasmid DNA Production

EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. ...

March 04, 2025 | News

Alphamab Oncology and CSPC Dose First Patient in Phase III Trial of JSKN003 for HER2-Positive Breast Cancer

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has...

February 28, 2025 | News

Stay Connected